FMT converts cancer immunotherapy non-responders to responders

Adding fecal microbiota transplantation to treatment in patients with programmed cell death protein 1 melanoma altered the gut microbiome and reprogrammed tumor microenvironment to overcome resistance to anti-programmed cell death protein 1 therapy, according to study results.“Our findings warrant further investigation in larger clinical trials to better identify microbial, circulating and intra-tumoral biomarkers to select patients most likely to benefit from microbiome-based therapy of melanoma,” Diwakar Davar, MD, from the department of medicine, University of PittsburghRead More

Share on facebook
Share on twitter
Share on linkedin